

Nivo/Ipi (nivolumab and ipilimumab) CheckMate 040

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects




Other adjustments



Nivo/Ipi (nivolumab and ipilimumab) CheckMate 040

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Patients with HCC who have been previously treated with sorafenib

Experimental Arm: Nivo/Ipi (nivolumab and ipilimumab)

Control Arm: Single arm (Phase II)

